Diary - News All news VALBIOTIS selected to present 3 studies on TOTUM-63

VALBIOTIS selected to present 3 studies on TOTUM-63

VALBIOTIS selected to present 3 studies on TOTUM-63
by the European Association for the Study of Diabetes (EASD)

EASD, the leading European association in the field of diabetes, has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.
Additionally, two preclinical studies have also been selected, providing a better understanding of the multitargeted mode of action of TOTUM-63 and its efficacy in prevention and reversion of weight gain and its impact in the carbohydrate metabolism.
The value of VALBIOTIS’ scientific and clinical work keeps gaining momentum, with increased recognition from the international scientific community.

La Rochelle, September 21, 2020 (7:35 am CEST) VALBIOTIS (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the selection of 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD), which will be presented at the association’s annual meeting in September 2020.